Taiwan Liposome Stock Forecast, Price & News

+0.21 (+2.98 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume22,269 shs
Average Volume14,280 shs
Market Capitalization$305.08 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TLC News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

Taiwan Liposome logo

About Taiwan Liposome

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.11 out of 5 stars

Medical Sector

1185th out of 1,349 stocks

Pharmaceutical Preparations Industry

578th out of 663 stocks

Analyst Opinion: 1.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Taiwan Liposome (NASDAQ:TLC) Frequently Asked Questions

Is Taiwan Liposome a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taiwan Liposome in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Taiwan Liposome stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLC, but not buy additional shares or sell existing shares.
View analyst ratings for Taiwan Liposome
or view top-rated stocks.

What stocks does MarketBeat like better than Taiwan Liposome?

Wall Street analysts have given Taiwan Liposome a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Taiwan Liposome wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Taiwan Liposome?

Taiwan Liposome saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 3,100 shares, a drop of 59.2% from the August 15th total of 7,600 shares. Based on an average trading volume of 43,100 shares, the days-to-cover ratio is currently 0.1 days.
View Taiwan Liposome's Short Interest

When is Taiwan Liposome's next earnings date?

Taiwan Liposome is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Taiwan Liposome

How were Taiwan Liposome's earnings last quarter?

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.16. The firm earned $5.74 million during the quarter, compared to analyst estimates of $0.80 million. Taiwan Liposome had a negative net margin of 299.27% and a negative trailing twelve-month return on equity of 120.45%.
View Taiwan Liposome's earnings history

How has Taiwan Liposome's stock been impacted by COVID-19 (Coronavirus)?

Taiwan Liposome's stock was trading at $3.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TLC shares have increased by 88.3% and is now trading at $7.25.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TLC?

3 brokers have issued 12-month target prices for Taiwan Liposome's stock. Their forecasts range from $7.50 to $7.50. On average, they expect Taiwan Liposome's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Taiwan Liposome
or view top-rated stocks among Wall Street analysts.

Who are Taiwan Liposome's key executives?

Taiwan Liposome's management team includes the following people:
  • Kee Lung Hong, Chairman & Chief Executive Officer
  • Chih Hung Yeh, President & General Manager
  • Yi Ju Chen, Head-Finance & Accounting
  • Yun Lung Tseng, Deputy General Manager-Research & Development
  • George Spencer-Green, Chief Medical Officer

Who are some of Taiwan Liposome's key competitors?

What other stocks do shareholders of Taiwan Liposome own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taiwan Liposome investors own include Gilead Sciences (GILD), Pfizer (PFE), Wells Fargo & Company (WFC), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Celldex Therapeutics (CLDX), Seabridge Gold (SA), Trevena (TRVN), AbbVie (ABBV) and Advanced Micro Devices (AMD).

When did Taiwan Liposome IPO?

(TLC) raised $29 million in an initial public offering on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

What is Taiwan Liposome's stock symbol?

Taiwan Liposome trades on the NASDAQ under the ticker symbol "TLC."

Who are Taiwan Liposome's major shareholders?

Taiwan Liposome's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.03%).

Which institutional investors are selling Taiwan Liposome stock?

TLC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Taiwan Liposome?

Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taiwan Liposome's stock price today?

One share of TLC stock can currently be purchased for approximately $7.25.

How much money does Taiwan Liposome make?

Taiwan Liposome has a market capitalization of $305.08 million and generates $3.63 million in revenue each year. The company earns $-35,020,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

What is Taiwan Liposome's official website?

The official website for Taiwan Liposome is

Where are Taiwan Liposome's headquarters?

How can I contact Taiwan Liposome?

Taiwan Liposome's mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886226557377 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.